Novartis India Limited Registered Office: Sandoz House Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018 India Tel +91 22 2495 8400 Fax +91 22 2495 0221 CIN No. L24200MH1947PLC006104 Website: www.novartis.in Email : india.investors@novartis.com

Quarterly Compliance Report on Corporate Governance

Novartis India Limited Quarter ending: December 31, 2015

I. Composition of Board of Directors

Title (Mr / Ms)	Name of the Director	DIN/PAN*	Category (Chairperson /Executive/ NonExecutive/independent/ Nominee)	Date of Appointment in the current term /cessation	Tenure	No of Directorship in listed entities including this listed entity (Refer Regulation 25(1) of Listing Regulations)	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)
Mr	Christopher Snook	00369790	Chairperson	01-08-2008	-	1	2	-
Mr	Ranjit Shahani	00103845	Executive	01-11-2015	-	1	1	-
Mr	Dinesh Charak	06827519	Executive	22-05-2014	-	1	1	-
Mr	Jai Hiremath	00062203	Independent	28-01-2006	11 years	2	2	2
Dr.	Rajendra Mehrotra	00172639	Independent	30-05-2000	15 years 8 months	2	3	2
Ms	Manisha Girotra	00774574	Independent	25-05-2014	1 year 6 months	3	-	-

*PAN no of the directors is disclosed to the Bombay Stock Exchange.

II. Composition of Committees

Name of Committee	Name of Committee members	Category (Chairperson/Executive/NonExecutive/inde pendent/Nominee)
1. Audit Committee	Mr Jai Hiremath Dr Rajendra Mehrotra Mr. Christopher Snook	Chairperson - Non Executive - Independent Non Executive - Independent Non- Executive
2.Nomination & Remuneration Committee	Dr Rajendra Mehrotra Mr. Christopher Snook Mr. Jai Hiremath	Chairperson - Non Executive - Independent Non-executive Non Executive - Independent
3. Risk Management Committee (if applicable)	NA	
4. Stakeholders Relationship Committee	Dr Rajendra Mehrotra Mr. Christopher Snook Mr. Ranjit Shahani Mr. Dinesh Charak	Chairperson - Non Executive - Independent Non - Executive Executive Executive

Novartis India Limited Registered Office: Sandoz House Shivsagar Estate Dr. Annie Besant Road Worli, Mumbai 400 018 India Tel +91 22 2495 8400 Fax +91 22 2495 0221 CIN No. L24200MH1947PLC006104 Website: www.novartis.in Email : india.investors@novartis.com

II. Meeting of Board of Directors

Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Maximum gap between any two consecutive meetings in number of days
July 22, 2015	November 5, 2015	105 days

III. Meeting of Committees

Date(s) of meeting of the committee in the relevant quarter	Whether requirement of Quorum met (details)	Date(s) of meeting of the committee in the previous quarter	Maximum gap between any two consecutive meetings in number of days
Audit Committee - November 5, 2015	Yes - All members attended the meeting	July 22, 2015	105 days
Stakeholder Relationship Committee – November 5, 2015	Yes - All members attended the meeting	July 22, 2015	105 days

IV. Related Party Transactions

Subject	Compliance status (Yes/No/NA)
Whether prior approval of audit committee obtained	Yes
Whether shareholder approval obtained for material RPT	Yes
Whether details of RPT entered into pursuant to omnibus approval	Yes
have been reviewed by Audit Committee	

Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 2. The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & remuneration committee
 - c. Stakeholders relationship committee
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.